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study should cover all indications for use, retrieve informa-
tion from a healthcare database, and include a defined set of 
covariates to avoid bias.  © 2014 S. Karger AG, Basel 
 Introduction 
 Antiepileptic drugs (AEDs) have been described as po-
tential risk factors for suicidal behavior  [1] . In 2008, the 
Food and Drug Administration (FDA) in the USA re-
ported a 2-fold increased risk of suicidal ideation or be-
havior for 11 AEDs (odds ratio, OR, 1.80, 95% confidence 
interval, CI, 1.24–2.66)  [2] .
 Suicide is a serious public health concern around the 
world. In 2011, the prevalence rate in Europe was 
13.9/100,000 persons per year  [3] , with the highest rates 
among men and older individuals, although the preva-
lence among adolescents and young adults has recently 
increased  [4, 5] . These figures are even higher among 
people with epilepsy; the reported lifetime prevalence rate 
of suicide and suicide attempts are between 5 and 14.3% 
 [6] . Psychological autopsy studies have demonstrated 
that 90% of suicide victims suffer from a psychiatric con-
dition at the time of death  [7] . 
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 Abstract 
 Background: Since the FDA (Food and Drug Administration) 
report on antiepileptic drugs (AEDs) and suicide risk was re-
leased (2008), several studies have been published on this 
controversial relationship. This systematic review (SR) gives 
an updated approach to this health issue.  Summary: We 
searched 6 databases. We ultimately included 11 publica-
tions: 4 cohort studies, 1 case-crossover study, 2 community 
case-control studies, and 4 SRs. Overall, 1 SR described stud-
ies already included; 3 studies reported a 2- to 4-fold overall 
increase in risk; 1 study reported an increased risk of suicide 
among epilepsy patients on AEDs with high risk of depres-
sion; 1study showed a protective effect among epilepsy pa-
tients; 2 studies were conducted with patients with bipolar 
disorder (1 showed a protective effect, whereas the other 
showed a 3-fold increase in risk of suicide), and the other 3 
studies reported results for single AEDs. Several biases af-
fected the published results.  Key Messages: There is no clear 
evidence of an association between the use of AEDs and an 
increased risk of suicide because of the heterogeneity in the 
studies at the clinical and methodological level. A future 
 Received: July 23, 2013 
 Accepted: October 29, 2013 
 Published online: January 3, 2014 
 Luisa Ibáñez 
 Pg Vall d’Hebron 119-129 
 ES–08035 Barcelona (Spain) 
 E-Mail li   @   icf.uab.es 
 
 © 2014 S. Karger AG, Basel
0251–5350/14/0422–0107$39.50/0 
 www.karger.com/ned 
 Ferrer  /Ballarín  /Sabaté  /Vidal  /Rottenkolber  /





 The following trends and observations led to this sys-
tematic review (SR): (1) the high and widespread use of 
AEDs to treat epilepsy and other conditions including 
off-label indications  [8–10] ; (2) the use of new AEDs 
among the elderly  [11, 12] ; (3) the fact that AED users 
have the highest risk of suicide within their population 
age group  [3] , and (4) the potential public health implica-
tions of the association between AEDs and suicide. The 
aim of this review is to systematically summarize the 
available evidence from randomized clinical trials (RCTs) 
and observational studies on the association between 
AEDs and suicide.
 Methods 
 Data Sources 
 We searched PubMed (1980–April 2012), the Cochrane Cen-
tral Register of Controlled Trials, the Cochrane Database of Sys-
tematic Reviews, the Database of Abstracts of Reviews of Effects 
(1980–February 2012), PsycINFO (1980–February 2012), and 
ClinicalTrials.gov (April 5, 2012). The search strategy included 
MeSH terms and free-text words. We combined the terms ‘anti-
epileptic drugs’ and each of the Anatomical Therapeutic Chemical 
Classification level 4 and 5 drugs for N03A (version 2012) with the 
terms ‘suicide’, ‘intentional self-murder’, ‘killing oneself’, ‘has-
tened death’, ‘subintended death’, ‘miscalculation’, ‘fatal self-
harm’, ‘suicide intent’, ‘suicide attempt’ and ‘suicide behavior’, us-
ing the Boolean operator AND. We included studies published in 
any language mastered by the authors P.F., E.B., M.S. and L.I. – 
English, any Romance language, and Swedish. We also electroni-
cally searched the following peer-reviewed journals:  Neuropsycho-
pharmacology, CNS Drugs, Neurology, all of the Lancet group pub-
lications,  Science Direct , and the Wiley Online Library. In addition, 
we reviewed the reference lists from the included studies. Two of 
the three authors we contacted provided additional information.
 Study Selection 
 We aimed to identify RCTs and observational studies related 
to any type of AED that included suicidality (defined as completed 
or attempted suicides) as a primary or secondary outcome. Studies 
that included suicidal ideation or deliberate self-harm with no in-
tention to die or unknown intention as outcomes were only in-
cluded if the authors also collected information on completed or 
attempted suicides, as defined by Posner et al.  [13] . 
 P.F. screened the titles and abstracts yielded by the bibliograph-
ic search, and E.B. screened the above-mentioned journals elec-
tronically to assess whether they met the eligibility criteria. We 
retrieved the full-text article if an abstract was selected or if there 
was uncertainty regarding the eligibility of a study. The inclusion 
criteria were RCTs or observational studies, and a population aged 
18 years or older. The reference group was placebo or no treat-
ment. We excluded case reports and studies conducted with data 
from spontaneous report databases.
 The search on ClinicalTrials.gov was limited to the trials that 
used a random allocation method, had a safety-related outcome 
and were limited by age ( ≥ 18 years). We excluded ongoing trials.
 Data Extraction and Quality Assessment 
 P.F. and E.B. extracted the data using a predetermined form. 
To better assess the heterogeneity between the studies, we devel-
oped a checklist specifically for this SR of adverse effects (see
online supplementary material; for all online suppl. material,
see www.karger.com/doi/10.1159/000356807). Any discrepancies 
were resolved by discussion.
 Data Synthesis 
 Because we expected clinical (e.g. different drug exposures, dif-
ferent participants, different indications for use, different defini-
tions of suicide) and methodological (inclusion of randomized and 
observational studies, different confounders included in the ad-
justed models) heterogeneity, we decided to conduct a narrative 
synthesis  [14] .
 Results 
 We initially included 10 publications. See  figure 1 for 
the numbers of studies that were screened, assessed for 
eligibility and included in the final analyses, as well as the 
reasons for exclusion; 1 prospective cohort study  [15] had 
flaws in its statistical results and was therefore excluded. 
Since this search was conducted, a new SR  [16] and a new-
user design study  [17] have been published and included 
in this SR. Ultimately, we included 11 published studies. 
For a description of the 11 included studies and the co-
hort study excluded, see  table 1 .
 Gibbons et al.  [18]  conducted 2 population-based pro-
spective cohort studies between 2000 and 2006 –1 study 
involving patients with bipolar disorder reported a risk of 
suicide for any AED of 0.88 (95% CI 0.72–1.08), and an-
other study  [19] which included patients who had filled 
one prescription of gabapentin showed an effect of this 
AED on suicide of 0.93 (95% CI 0.76–1.14). Gabapentin 
on patients with bipolar disorder in this study showed a 
protective effect (OR 0.62, 95% CI 0.41–0.94). In both 
studies, the measurement of the exposure did not account 
for compliance, dosage and duration of treatment, and it 
focused on any use over a time span of 1 year. This meth-
odology may have led to nondifferential exposure mis-
classification. Suicide may have been underreported, re-
sulting in nondifferential outcome misclassification. Not 
all potential confounders were considered, although in 
the study of the bipolar patients, the authors adjusted for 
suicide attempts in the year before the diagnosis. 
 Sondergård et al.  [20] found an increased risk of sui-
cide associated with one prescription of any AED among 
patients with a severe bipolar disorder (OR 3.30, 95% CI 
2.17–4.99); however, they did not consider previous sui-
cide attempts or other cotreatments in the model. In an 
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attempt to control for confounding by indication they ad-
justed for readmission and the use of lithium as a marker 
of bipolar disorder severity. The number of prescriptions 
was a proxy measure for the duration of treatment. They 
did not consider dosage or compliance.
 In the case-crossover analysis of Olesen et al.  [21] , the 
authors found a 2-fold increased risk of suicide with the 
use of AEDs (OR 1.84, 95% CI 1.36–2.49).There was a 
potential for nondifferential exposure misclassification 
(as an average daily dose was calculated instead of use of 
Excluded n = 119
Unable to obtain information required for
assessment = 22
No placebo comparison = 15
Did not assess suicide = 39
No effect measure calculated = 29
Reviews with studies already included = 2
Type of population = 5
Mixed intervention = 7
Excluded n = 736
Type of study = 226
Language = 16
No abstracts = 27
Duplicates = 7
No intervention of interest = 284
No outcome of interest = 176























Clinical trials with a
safety-related outcome
n = 10
Excluded n = 10
Results not available = 5
Did not assess suicide = 5
 Fig. 1. Results of the search strategy. 
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prescribed daily dose) and for confounding by changes in 
indication or the severity of the risk of suicide over time. 
The authors did not state the reason for the time window 
they selected and failed to include sensitivity analyses for 
different time exposure windows. There is also a potential 
for reverse causation bias. The cohort analysis was not 
considered in this review as the reference drug was carba-
mazepine.
 There were 2 community-based case-control studies. 
On the one hand, Arana et al.  [22] reported an association 
between suicide and the use and nonuse of AEDs in 11 
cohorts and concluded that the increased risk was depen-
dent on the underlying disease. On the other hand, they 
also reported an increased risk of suicide in patients on 
AEDs without epilepsy, depression or bipolar disorder 
(OR 2.57, 95% CI 1.78–3.71). The authors reported that 
17% of these patients had a pain-related diagnosis. In the 
subgroup analyses, comparing current users and nonus-
ers of AEDs, the current use of AEDs provided a protec-
tive effect for patients with epilepsy alone (OR 0.59, 95% 
CI 0.35–0.98); however, patients with depression alone 
had an increased risk of suicide (OR 1.65, 95% CI 1.24–
2.19). Conversely, in patients with bipolar disorder, the 
use of AEDs seemed uneventful (OR 1.13, 95% CI 0.35–
3.61). Andersohn et al.  [23] showed that only AEDs with 
high risk of depression were associated with an increased 
risk of suicide in epilepsy patients (OR 3.08, 95% CI 1.22–
7.77). In both studies  [22, 23] , the results could be biased 
by confounding by indication. Furthermore, there was a 
possibility of nondifferential outcome misclassification 
because suicides may have been underestimated. Residu-
al confounding from the type of epilepsy was also a pos-
sible explanation for the results in the study of Andersohn 
et al.  [23] because the code-defined diagnoses for type of 
epilepsy were not validated. The small numbers of cases 
and controls could have also decreased the power of the 
study to detect an effect, particularly for individual drugs. 
In the study of Arana et al.  [22] , the authors excluded all 
individuals with a familial or personal history of suicide, 
which could have led to an overall underestimation of the 
risk of suicide.
 Pugh et al.  [17] conducted a study with in- and outpa-
tients aged 65 years and older. Demographic, psychiatric 
comorbidity and chronic pain variables were used to con-
struct a propensity score to control for confounding in 
the model. The authors reported a hazard ratio of 3.90 
(95% CI 2.93–5.19) for any AED use. The authors did not 
assess the effect of prevalent users on the results. Except 
for levetiracetam, marketed in 2004, all the other AEDs 
have long been on the market. Thus, some of the patients 
included may not have been naive to AEDs. The authors 
developed a propensity score model and gave a c-statistic 
value of 0.66. The c-statistic tells us how well the model 
with the observed covariates predicted the probability of 
receiving an AED. The c-statistic usually ranges between 
0.5 (chance classification) and 1 (perfect classification) 
 [24] . However, Pugh et al.  [17] did not provide the distri-
bution of the propensity scores among the AED users and 
nonusers, which would have been more informative of 
the distribution of the confounders between groups  [24] . 
Thus, it was difficult to assess whether there was any error 
in their estimation. In addition, there was the potential 
for nondifferential misclassification of suicide.
 Three SRs  [2, 25, 26] included randomized trials of ef-
ficacy; suicide was collected as a potential adverse event 
in these trials. The FDA’s meta-analysis  [2] reported an 
increased risk of suicide for all AEDs (OR 1.80, 95% CI 
1.24–2.66). Van Lieshout and MacQueen  [25] and Prem-
kumar and Pick  [26] reported on the effects of lamotri-
gine on suicide in patients with bipolar disorder and de-
pression (OR 0.26, 95% CI 0.02–2.77) and with schizo-
phrenia (OR 2.97, 95% CI 0.12–72.18). The results of all 
these 3 SRs could have suffered from an ascertainment 
bias of adverse events, even though the FDA’s meta-anal-
yses used a standardized protocol to detect and assess po-
tential suicide events  [2] . In the FDA’s meta-analysis, sui-
cide was described post hoc by the sponsor of the drug. In 
addition, there were differences in the duration of treat-
ment and treatment discontinuation between the placebo 
and treatment arms, with higher rates of discontinuation 
in the drug arm and a longer duration in the placebo arm. 
 The review by Fountoulakis et al.  [16] concluded that 
there were not enough data to confirm the association 
between an increased risk of suicide and AEDs as a group. 
With regard to individual drugs, they concluded that la-
motrigine and topiramate may increase the risk of sui-
cide, whereas carbamazepine and valproic acid were pro-
tective. However, this review searched a single biblio-
graphic database. It included all population subgroups 
except patients with mood disorders, any type of com-
parator except studies that only compared AEDs and lith-
ium, and any type of suicidal behavior. The authors re-
stricted the type of studies to those with a naturalistic de-
sign, database studies and prospective trials, without 
further specifications. They did not assess the quality of 
the included studies.
 Concerning individual drugs, studies have shown an 
increased risk of suicide for patients taking phenobarbital 
(1 study  [21] ), phenytoin (1 study  [17] ), carbamazepine 
(1 study  [22] ), valproic acid (3 studies  [17, 21, 22] ), la-
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General population Epilepsy Mental illness Other disorder Study
All antiepileptic 3.90 (2.93 – 5.19) Pugh [17], 2012
drugs 0.19 (0.08 – 0.47) Gibbons [18], 2009
1.84 (1.36 – 2.49) Olesen [21], 2010
Epilepsy only:
0.59 (0.35 – 0.98)
Epilepsy and depression: 
1.24 (0.56 – 2.72)
Depression:
1.65 (1.24 – 2.19)
Bipolar disorder:
1.13 (0.35 – 3.61)
No epilepsy, no depres-
sion, no bipolar disorder: 
2.57 (1.78 – 3.71)
Arana [22], 2010 (by 
indication)
AEDs with high risk of 
depression:
3.08 (1.22 – 7.77)
AEDs with low risk of
depression: 0.87 (0.47 – 1.59)
Andersohn [23], 2010
1.80 (1.24 – 2.66) 3.53 (1.28 – 12.1) 1.51 (0.95 – 2.45) 1.87 (0.81 – 4.76) FDA [2], 2008 (by
indication)
0.88 (0.72 – 1.08) Gibbons [18], 2009
1 prescription vs. none:
3.30 (2.17 – 4.99)
Sondergård [20], 2008
Phenobarbital 1.65 (0.40 – 6.74) Pugh [17], 2012
1.96 (1.02 – 3.75) Olesen [21], 2010
0.66 (0.23 – 1.90) Andersohn [23], 2010
Phenytoin 5.33 (1.55 – 18.3) Pugh [17], 2012
0.37 (0.03 – 4.44) Olesen [21], 2010
0.67 (0.42 – 1.08) Andersohn [23], 2010
Carbamazepine 1.19 (0.30 – 4.68) Pugh [17], 2012
0.48 (0.21 – 1.12) Olesen [21], 2010
No epilepsy, no depres-
sion, no bipolar disorder: 
1.35 (1.02 – 1.79)
Arana [22], 2010
0.83 (0.57 – 1.20) Andersohn [23], 2010
0.65 (0.08 – 4.42) FDA [2], 2008
Valproic acid 15.44 (9.4 – 25.4) Pugh [17], 2012
0.73 (0.51 – 1.02) Gibbons [18], 2009
2.08 (1.04 – 4.16) Olesen [21], 2010
No epilepsy, no depres-
sion, no bipolar disorder: 
1.44 (0.99 – 2.08)
Arana [22], 2010
0.68 (0.56 – 1.01) Andersohn [23], 2010
0.72 (0.29 – 1.84) FDA [2], 2008
Lamotrigine 36.6 (15.9 – 84.5) Pugh [17], 2012
0.85 (0.62 – 1.16) Gibbons [18], 2009
3.15 (1.35 – 7.34) Olesen [21], 2010
No epilepsy, no depres-
sion, no bipolar disorder: 
1.07 (0.58 – 1.98)
Arana [22], 2010
0.93 (0.49 – 1.76) Andersohn [23], 2010
0.26 (0.02 – 2.77) Van Lieshout [25], 2010
2.08 (1.30 – 4.40) FDA [2], 2008
2.97 (0.12 – 72.18) Premkumar [26], 2006
Topiramate 6.83 (1.9 – 24.51) Pugh [17], 2012
1.87 (1.22 – 2.87) Gibbons [18], 2009
2.72 (0.23 – 32.78) Olesen [21], 2010
No epilepsy, no depres-
sion, no bipolar disorder: 
0.52 (0.15 – 1.78)
Arana [22], 2010
2.42 (0.54 – 10.77) Andersohn [23], 2010
2.53 (1.21 – 5.85) FDA [2], 2008
Table 2.  Effect measure (95% CI) by drug and by subgroup of population
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motrigine (3 studies  [2, 17, 21] ), topiramate (3 studies  [2, 
17, 18] ), gabapentin (1 study  [17] ) and levetiracetam (2 
studies  [17, 23] ). However, a similar number of studies 
demonstrated a protective effect – valproic acid (1 study 
 [23] ) and gabapentin (1 study  [19] ) – or no effect – phe-
nobarbital (2 studies  [17, 23] ), phenytoin (2 studies  [21, 
23] ), valproic acid (3 studies  [2, 18, 22] ), lamotrigine (5 
studies  [18, 22, 23, 25, 26] ), topiramate (2 studies  [22, 
23] ), gabapentin (5 studies  [2, 18, 21–23] ), levetiracetam 
(3 studies  [2, 22] ) and oxcarbazepine (3 studies  [2, 18,
21] ) – of these AEDs on suicide.
 Table 2 shows the effect measures and the correspond-
ing 95% CIs grouped by population subgroup and/or in-
dication for use and AEDs.
 Discussion 
 Since the publication of the FDA alert on the risk of 
suicide associated with 11 AEDs, several observational 
studies  [27, 28] , as well as reviews and expert opinions 
 [29–32] , have attempted to disentangle this controversial 
relationship. We ultimately reviewed 11 studies that re-
ported findings on the effects of AEDs on suicide com-
pared to a placebo or no treatment; 3 studies  [2, 17, 21] 
reported a 2- to 4-fold overall increased risk of suicide 
with AEDs as a group. For epilepsy, the FDA meta-anal-
ysis  [2] showed an increased risk of suicide, whereas Ara-
na et al.  [22]  did not find an increased risk of suicide for 
patients with epilepsy, but did find an increased risk of 
suicide in depressive patients. However, the close rela-
tionship between epilepsy and other neurological and 
psychiatric disorders has determined the use of AEDs for 
different indications  [33] . Andersohn et al.  [23] showed 
that the risk of suicide in epilepsy patients depended on 
whether the AEDs had a high or low risk of depression. 
Concerning mental illness, Arana et al.  [22] showed an 
increased risk of suicide among patients with depression, 
but not among patients with bipolar disorder. Sondergård 
et al.  [20]  showed that any AED could increase the risk of 
suicide in patients with bipolar disorder under specialty 
out- and inpatient care. Gibbons et al.  [18] showed a pro-
tective effect of AEDs for the same type of patients, al-
though this study included the outpatient healthcare sec-
tor and as it required a 1-year follow-up of patients to be 
included, patients who committed suicide during this 
time period might have been excluded. In the study of 
Arana et al.  [22] it seemed that the effect of AEDs on bi-
polar patients was uneventful. For indications other than 
epilepsy, depression and bipolar disorder, Arana et al. 
[22] showed a 3-fold increased risk of suicide.
 For Pugh et al.  [17] and Sondergård et al.  [20] the use 
of AEDs may be a marker of disease severity, as patients 
in hospital have an increased risk of suicide attempts. 
Moreover, in Pugh et al.  [17] , depression and previous 
suicidality were more prevalent among patients exposed 
General population Epilepsy Mental illness Other disorder Study
Gabapentin 2.56 (1.96 – 4.16) Pugh [17], 2012
0.93 (0.76 – 1.14) 0.83 (0.34 – 2.04) All psychiatric diagnoses: 
0.73 (0.54 – 0.99)
Pain disorder:
0.99 (0.76 – 1.14)
Gibbons [18], 2010
1.16 (0.66 – 2.05) Gibbons [18], 2009
2.20 (0.83 – 5.83) Olesen [21], 2010
No epilepsy, no depres-
sion, no bipolar disorder: 
0.89 (0.45 – 1.77)
Arana [22], 2010
0.70 (0.18 – 2.75) Andersohn [23], 2010
1.57 (0.12 – 47.66) FDA [2], 2008
Levetiracetam 8.23 (1.41 – 48.11) Pugh [17], 2012
No epilepsy, no depres-
sion, no bipolar disorder: 
0.70 (0.12 – 4.0)
Arana [22], 2010
6.42 (1.24 – 33.36) Andersohn [23], 2010
2.75 (0.62 – 19.36) FDA [2], 2008
Oxcarbazepine 0.98 (0.62 – 4.56) Gibbons [18], 2009
0.84 (0.30 – 2.32) Olesen [21], 2010
1.91 (0.15 – 56.33) FDA [2], 2008
Table 2 (continued)
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to AEDs. Confounding by indication could partly ex-
plain their results. In the study of Olesen et al.  [21] , dur-
ing the case time period an increased risk of suicide 
could precede the prescription of an AED. Several stud-
ies presented in this review  [18, 20, 21] did not adjust for 
previous suicidal behavior, which has been reported as 
the most significant risk factor for attempted and com-
pleted suicides  [34] . Gibbons et al.  [18] adjusted for sui-
cide attempts in the year before the diagnosis of bipolar 
disorder. Andersohn et al.  [23]  reported that they ad-
justed for prior suicidal behavior, but the extent of the 
adjustment was unclear. The same issue applied in the 
adjustment for the type of epilepsy. Residual confound-
ing could have masked the effect of an association in all 
of the observational studies we included. In the FDA’s 
meta-analysis  [2] , the epilepsy patients took the AED 
under study as an adjuvant to other AEDs, which may 
indicate more severe disease. Suicide in this group of 
patients could be related to the ‘forced normalization’ 
phenomenon  [35] . 
 Another potential flaw in all the studies presented in 
this review is the nondifferential misclassification of sui-
cide which was assumed to be a limitation in all health-
care database studies. Theoretically, nondifferential dis-
ease misclassification would bias the effect estimate to-
wards the null, which may cause a problem for 
interpreting the results of studies reporting a null or very 
weak association between AEDs and suicide  [36] . There 
was no description of how adverse events were collected 
or how causality of an adverse event to the drug was as-
sessed in the clinical trials reviewed in the included SRs. 
In the FDA’s meta-analysis  [2] , adverse events were mea-
sured retrospectively based on the patient’s spontaneous 
reports.
 The dosage of the treatment and the compliance could 
not be estimated in several observational studies  [17, 18–
23] . This fact could introduce nondifferential exposure 
misclassification. Andersohn et al.  [23] did calculate the 
duration of the prescription minimizing this type of bias. 
The nondifferential misclassification of AEDs could bias 
the effect estimate towards the null. Furthermore, many 
studies  [17–19, 21] focused on ‘ever use’ of an AED over 
a long time span, which may also have biased the effect 
estimate towards the null.
 This review showed that the effect estimates were het-
erogeneous across populations or by indication. An ex-
planation for these contradictory findings could be, for 
example, that the patients on AEDs represented a sub-
group of patients at particularly high risk of suicide, and 
AEDs would serve as a marker for the severity of disease. 
 The main strength of this SR is that we included stud-
ies that had a placebo or nontreatment group as the refer-
ence group. The inclusion of randomized and observa-
tional studies resulted in a broad overview of the relation-
ship between AEDs and suicide. Another strength of this 
study is the standardized narrative synthesis. In an at-
tempt to assess clinical heterogeneity we grouped the 
study results by population subgroup or by indication. 
Because of the few numbers of studies we could not group 
by type of study. Comparing the results between studies 
is difficult because of the differences in the definition of 
the exposure or outcome as well as the confounders ad-
justed for in the statistical model. In addition, we devel-
oped a checklist to assess the studies we included in this 
SR of adverse effects. Although this checklist needs to be 
validated, it is a step toward assessing the quality of any 
type of study included in such SRs.
 Even though we searched in several bibliographic da-
tabases, we did not search EMBASE, which is a comple-
mentary bibliographic database to the PubMed database. 
We did not attempt to search gray literature. Hence, there 
is potential for publication bias. Moreover, we did not 
identify any clinical trials, although they were in our in-
clusion criteria. However, we assessed the effect of AEDs 
on suicide using SRs that included randomized trials of 
AED efficacy. This problem was the result of the diffi-
culty in searching the bibliographic databases for adverse 
events in RCTs on efficacy. It is unlikely that clinical trials 
include any terms related to assessment of adverse events 
in their titles, abstracts or keywords. 
 In an attempt to overcome some of the flaws detected 
in the published studies we believe that a new study 
should be conducted retrieving the information from a 
large healthcare database because suicide is a rare event. 
The exposure to AEDs should be as detailed as possible to 
account for the duration of the exposure. In addition, to 
avoid outcome misclassification, the study should try to 
link the database with a mortality register to better cap-
ture the causes of death, or search for cases in the database 
using free words. Alternatively, a review of a sample of 
medical charts to validate the diagnoses could be con-
ducted to ensure the detection of all potential cases. Due 
to the close relationship between several neuropsychiatric 
disorders and suicide, and the perils of confounding by 
indication, all of the diagnostic codes for the covariates 
relevant to the study should also be validated. We propose 
a set of confounders: epilepsy (type, age at onset, mono- 
or polytherapy), mood disorders, schizophrenia, neuro-
pathic pain or other indications including off-label use, 
antipsychotics, other central nervous system drugs, per-
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sonal history of previous suicide attempts, and socioeco-
nomic status. Age and gender should be considered po-
tential effect modifiers. Ideally, the severity of the diseas-
es included as confounders should be thoroughly assessed, 
directly or through a proxy variable such as referrals to 
the hospital or to specialty care. In addition, any new RCT 
conducted to determine the efficacy of a new AED or to 
determine a new AED indication should include suicidal-
ity as a specific safety-related outcome.
 Conclusions 
 There is no clear evidence to confirm or rule out an 
association between the use of AEDs and suicide because 
of the heterogeneity at the clinical and the methodologi-
cal level. 
 Most of the studies considered an overall effect of 
AEDs as a single class effect. This assumption may need 
to be revisited in light of the different effects of the differ-
ent AEDs on mood. 
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